SmallCapReview.com is a leading small cap stock information site since 1999, to register for the free SmallCapReview newsletter visit http://www.smallcapreview.com/.
Hawaiian Airlines (Nasdaq: HA) $3.91. Announced yesterday after market close its system wide traffic statistics for March. The Company carried 714, 320 passengers in March asn increase of 17.7& over March 2008.
Hawaiian also reported that, based on preliminary data, it expects Passenger Revenue per ASM (PRASM) to increase between 3.5% and 5.5% for the three months ended March 31, 2009, compared to the same period in 2008, exceeding the previous expectations the company disclosed during a conference call with investors on February 18, 2009, following the release of the Company's 2008 financial results. Hawaiian Holdings is a Focus Stocks at SmallCapReview.com.
What They Do: Hawaiian Holdings, Inc., through its subsidiary, Hawaiian Airlines, Inc., engages primarily in the scheduled air transportation of passengers and cargo in the United States. It offers daily service on transpacific routes between Hawaii and Los Angeles, Sacramento, San Diego, San Francisco, San Jose, Las Vegas, Phoenix, Portland, and Seattle, as well as daily service among the Hawaiian Islands, and additional service to Australia, American Samoa, and Tahiti. The company also provides charter service from Honolulu to Anchorage, Alaska. As of December 31, 2007, it operated a fleet of 11 Boeing 717-200 aircraft for its inter island routes and a fleet of 18 Boeing 767-300 aircraft for its transpacific, South Pacific, and charter routes.
Merck & Co. (NYSE: MRK) $26.76, and Cardiome Pharma Corp. (Nasdaq: CRME) $3.18. Announed yesterday after market close a collaboration and license agreement for the development and commercialization of vernakalant, an investigational candidate for the treatment of atrial fibrillation. The agreement provides Merck with exclusive global rights to the oral formulation of vernakalant (vernakalant [oral]) for the maintenance of normal heart rhythm in patients with atrial fibrillation, and provides a Merck affiliate, Merck Sharp & Dohme (Switzerland) GmbH, with exclusive rights outside of the United States, Canada and Mexico to the intravenous (IV) formulation of vernakalant (vernakalant [IV]) for rapid conversion of acute atrial fibrillation to normal heart rhythm.
What They Do: Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system.
Caterpillar Inc. (NYSE: CAT) $29.57. Today announced that The Board of Directors declared a quarterly cash dividend of forty-two ($0.42) cents per share of common stock, payable May 20, 2009, to stockholders of record at the close of business April 20, 2009.
"There are significant economic challenges in today's global economy, and Caterpillar is assertively addressing the requirement to significantly reduce production levels," said Caterpillar Chairman and Chief Executive Officer Jim Owens. "Given this challenging environment, and the uncertainty it creates, I am pleased we have maintained our dividend rate for our stockholders."
The $0.42 dividend maintains the dividend rate from the previous quarter and is 17 percent higher than the dividend paid one year ago. Including the announcement today, Caterpillar's cash dividend has nearly tripled since 1998.
What They Do: For more than 80 years, Caterpillar Inc. has been making progress possible and driving positive and sustainable change on every continent. With 2008 sales and revenues of $51.324 billion, Caterpillar is the world's leading manufacturer of construction and mining equipment, diesel and natural gas engines and industrial gas turbines.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for news on small-cap stocks since 1999. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select small-cap stocks, to register visit http://www.smallcapreview.com/.
